CELL INTELLIGENCE · 肿瘤细胞治疗研究

This study was conducted on 112 participants divided into two equal groups: Group I, 56 patients with liver cirrhosis and different stages of HCC; Group II, 56 patients with liver cirrhosis. The diagnosis of HCC was based on AASLD guidelines. TNM and BCLC classification systems are used for staging of HCC.

A significant reduction in the median percentage of lymphocyte subset (CD3 + , CD4 + , CD8 + , CD19 + ) and NK cell percentage (CD56 + ) has been detected in HCC patients (all P < 0.001). In the HCC group the median monocyte subpopulations CD14 + CD16 - Classical, CD14 ++ CD16 + Intermediate, and CD14 -+ CD16 ++ Non-Classical were 11.7, 4.0, and 3.5, respectively, with marked reduction compared with liver cirrhosis group (all P < 0.001). Patients with advanced stages (BCLC C and D) were more likely to have significantly higher median CD33 + than patients with early stages (BCLC A and B) ( P = 0.05); also, the median levels of HLA DR + lymphocytes % in the HCC case group were 21.8 in patients with advanced disease (BCLC C and D) and 13.1 in patients with early stages of the disease ( P = 0.04). Patients with late stage (TNM III) were more likely to have significantly higher median CD14 + CD16 - Classical monocyte subset, CD36 + HLA DR + , and CD36 + CD16 - than patients with early stages (TNM I and II).

Patients with HCC with unremarkable raised AFP showed marked reduction in lymphocytes, natural killer cells, and all monocyte subpopulations. In addition, patients with advanced HCC showed increased CD33 + and HLA DR + lymphocytes %, CD14 + CD16 - Classical monocyte subset, CD36 + HLA DR + , and CD36 + CD16 - compared with patients with early stages of HCC.